1
|
Manzar GS, Wu SY, Dudzinski SO, Jallouk A, Yoder AK, Nasr LF, Corrigan KL, Gunther JR, Ahmed S, Fayad L, Nair R, Steiner R, Westin J, Neelapu SS, Dabaja B, Strati P, Nastoupil L, Pinnix CC, Fang P, Rooney MK. Outcomes with Bridging Radiation Therapy Prior to CAR-T Cell Therapy in Pts with Aggressive B Cell Lymphomas. Int J Radiat Oncol Biol Phys 2023; 117:e483-e484. [PMID: 37785529 DOI: 10.1016/j.ijrobp.2023.06.1708] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Select patient (pts) with relapsed/refractory aggressive B cell lymphoma may benefit from bridging radiation (bRT) prior to anti-CD19-directed chimeric antigen receptor T cell therapy (CART). Here, we examined pt and treatment factors associated with outcome after bRT and CART. MATERIALS/METHODS We retrospectively reviewed adults with DLBCL who received bRT prior to axicabtagene ciloleucel 11/2017-12/2022. Clinical/treatment characteristics, response, and toxicity were extracted. Progression free survival (PFS), disease specific survival (DSS) and overall survival (OS) were modeled using Kaplan-Meier for events distributed over time, or binary logistic regression for disease response. Fisher's Exact Test or Mann-Whitney U methods were used. RESULTS Among 40 pts, 11 (28%) had limited stage disease at apheresis, and 14 (35%) received bRT in addition to bridging systemic therapy. Thirty-two (80%) pts received bRT post-leukapheresis. bRT was delivered with a median dose of 30 Gy (range: 4-46) in 10 fractions (range: 2-23). Eighteen (45%) pts received <30 Gy. Twenty-two pts (55%) received bRT comprehensively to all sites of disease, including 9 pts who had limited stage. Eleven pts had bulky disease (≥ 10 cm) at the time of bRT. After CART, 4 pts (10%) experienced Grade ≥3 cytokine release syndrome (CRS), 16 (40%) had Grade ≥2 CRS, and 16 (38%) had Grade ≥3 neurotoxicity. Twenty-three pts (57.5%) had CR at 30 days post-CART infusion. Nine had PR (22.5%), of whom 2 pts eventually developed CR at three months and 1 at nine months. Eight pts (20%) had either PD or SD. Of 23 pts who experienced CR, 11 relapsed-6 at three months and 5 at six months. At a median follow up of 9.6 months (95% CI: 6.6-16.2), 22 pts relapsed: 6 (27.3%) in-field, 10 (5.5%) out-of-field, 4 (18.2%) both, and 2 (9.1%) unknown. The median PFS was 8.87 months and median OS was 22 months. PFS at 1 year was 70% (53-82) and at 2 years was 42% (27-57). OS at 1 and 2 years was 72.5% (56-84) and 51% (34-65), respectively. Seventeen pts (42.5%) remain alive at last follow-up, 13 (76.5%) of whom have no evidence of disease (NED). On univariate analysis, OS and PFS at 1 year were 67% (43-83) and 49% (27-68) for those who received RT comprehensively (n = 22), and 41.9% (19-64) and 33.3% (14-54) for those who did not (n = 18; both p≤0.03). Disease bulk (≥10 cm) was associated with significant decrement in DSS (p = 0.03), but not PFS (p = 0.16) or OS (p = 0.24). Among pts treated comprehensively with bRT (n = 22), there was no association of tumor bulk with OS, PFS, or DSS (p>0.2). IPI ≥3 was associated with worse DSS (p = 0.045) and trended towards worse PFS (p = 0.054), but not OS (p = 0.23). There was no difference in PFS, OS, or DSS between pts who received bRT or chemoRT (p>0.3). CONCLUSION bRT and CART is a good treatment strategy for select pts with aggressive B cell lymphoma. When feasible, and with a caveat that other variables influence patient disposition, bRT for CART is associated with improved outcomes after comprehensive RT to all sites of disease.
Collapse
Affiliation(s)
- G S Manzar
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Y Wu
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S O Dudzinski
- Vanderbilt University School of Medicine, Nashville, TN
| | - A Jallouk
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - A K Yoder
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - L F Nasr
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - K L Corrigan
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - J R Gunther
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Ahmed
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - L Fayad
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - R Nair
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - R Steiner
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - J Westin
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S S Neelapu
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - B Dabaja
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - P Strati
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - L Nastoupil
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - C C Pinnix
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - P Fang
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - M K Rooney
- Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
2
|
Cha E, Manzar GS, Corrigan KL, Yoder AK, Schrank BR, Nasr LF, Gunther JR, Strati P, Ahmed S, Fayad L, Nair R, Steiner R, Westin J, Nastoupil L, Neelapu SS, Pinnix CC, Dabaja B, Wu SY, Fang P. Outcomes and Toxicities in Patients with Diffuse Large B-Cell Lymphoma of the Gastrointestinal Tract. Int J Radiat Oncol Biol Phys 2023; 117:e460. [PMID: 37785475 DOI: 10.1016/j.ijrobp.2023.06.1655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Diffuse large B-cell lymphoma (DLBCL) involving the gastrointestinal (GI) tract is rare and long-term outcomes are not well defined. Combined modality therapy (CMT) with radiotherapy (RT) in addition to systemic therapy in this setting is not commonly pursued. We aim to characterize outcomes in patients with GI DLBCL treated with systemic therapy, with or without RT. MATERIALS/METHODS Patients diagnosed with DLBCL of the GI tract (with or without mesenteric involvement) treated at a single institution from 1988-2022 were retrospectively reviewed on an IRB-approved protocol. Clinical and treatment data were collected including adverse events (AE; acute vs late defined as before or 4 weeks after therapy end). Kaplan-Meier and Cox regression models were used to estimate survival. RESULTS Of 207 patients, 62% were male and median age at diagnosis was 63 (IQR 52-73). Gastric involvement was most common (n = 130, 63%), followed by small intestines (n = 48, 23%) and colon/rectum (n = 24, 12%). Most presented with early-stage disease (n = 124, 60%), with a median IPI score of 1. All patients received chemotherapy. Of 182 treated with CHOP/EPOCH, 36 (20%) were treated in the pre-rituximab era while 146 (80%) received rituximab. 66 patients (32%) were treated with RT, 89% as part of first line CMT. 50 cases (76%) received consolidative RT, while 10 (15%) targeted residual gross disease and 4 (6%) targeted distant sites. Median dose and fractionation were 36Gy (IQR 30.6-39.6) in 18 fractions (IQR 17-22). Over half (n = 132, 64%) developed grade 3+ acute chemotherapy AEs, and the most common were anemia (n = 64), febrile neutropenia (n = 40), and neutropenia (n = 20). Grade 3+ late chemotherapy AEs occurred in 14 patients (7%). Acute grade 3+ radiation AEs were uncommon (n = 2, 3%; colitis, emesis). No grade 3+ late radiation AEs were noted. Median follow-up was 46 months (IQR 16-97). 169 (81.6%) had a complete response (CR), with 154 (91%) after first line chemotherapy, 9 (5%) after second line, and 6 (4%) after RT. CR was defined by PET (62%), endoscopy (22%), CT (9%), or other methods (7%). The 5-year progression-free survival for those treated with one line of chemotherapy with or without RT was 95%. Median overall survival (OS) was not reached. Improved OS was associated with early-stage disease (p = 0.003), low IPI (p = 0.001), fewer chemotherapy lines (p<0.001), and CR (p<0.001). OS did not differ by gender, age, immunophenotype, GI site, SUVmax, or RT. Patients with early stage DLBCL treated with RT in the post-rituximab era received fewer chemotherapy cycles compared to those treated without RT (p = 0.02; median of 4 (IQR 3-6) vs 6 cycles (IQR 4-6)), with no OS difference. CONCLUSION GI DLBCL patients have favorable outcomes after CMT with minimal late toxicity. CMT with RT to the GI tract is well tolerated with no OS difference compared to chemotherapy alone, and may mitigate risks from additional chemotherapy cycles for selected early-stage patients.
Collapse
Affiliation(s)
- E Cha
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - G S Manzar
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - K L Corrigan
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - A K Yoder
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - B R Schrank
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - L F Nasr
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - J R Gunther
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - P Strati
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Ahmed
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - L Fayad
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - R Nair
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - R Steiner
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - J Westin
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - L Nastoupil
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S S Neelapu
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - C C Pinnix
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - B Dabaja
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Y Wu
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - P Fang
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
3
|
Manzar GS, Wu SY, Dudzinski SO, Rooney MK, Jallouk A, Yoder AK, Nasr LF, Gunther JR, Sallard G, Ahmed S, Fayad L, Nair R, Steiner R, Westin J, Nastoupil L, Neelapu SS, Dabaja B, Pinnix CC, Strati P, Fang P. Characterization of Lymphopenia during Bridging Radiation Therapy Prior to CAR-T Cell Therapy in Patients with Aggressive B Cell Lymphomas. Int J Radiat Oncol Biol Phys 2023; 117:S53-S54. [PMID: 37784520 DOI: 10.1016/j.ijrobp.2023.06.337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Bridging RT (bRT) may be used as a strategy for disease control in patients with relapsed/refractory aggressive B cell lymphoma treated with anti-CD19-directed chimeric antigen receptor T-cell therapy (CART). The correlation of treatment-related lymphopenia with adverse outcomes in patients has been widely documented in several malignancies. Here, we assessed lymphocyte kinetics during bRT and impact on clinical outcome. MATERIALS/METHODS After IRB-approval, records were retrospectively reviewed for adults with DLBCL who received bRT for axicabtagene ciloleucel 11/2017-12/2022. Clinical/treatment characteristics, lab values, and outcomes were extracted. ALC Δ RT was computed by subtracting pre-RT ALC from post-RT ALC count. Survival was modeled using Kaplan-Meier for events distributed over time, or binary logistic regression for disease response. Fisher's Exact Test or Mann-Whitney U methods were used. RESULTS Forty patients met inclusion criteria. Fourteen (35%) received bRT with systemic therapy. Thirty-two (80%) patients received bRT that started post-leukapheresis. bRT was delivered with a median dose of 30 Gy (range: 4-46) in 10 fractions (range: 2-23). Twenty-three patients (57.5%) had CR at 30 days post-CART infusion. Nine had PR (22.5%), and 8 patients (20%) had PD or SD. Median PFS was 8.9 months and median OS was 22 months. The pre-RT ALC mean ± SD was 0.74 ± 0.49 K/µL, and post-RT was 0.43 ± 0.35 K/µL. The absolute ALC Δ RT was 0.31 ± 0.43 K/µL, and ratio post-RT/pre-RT was 0.74 ± 0.64. Stratifying by receipt of bRT alone or with systemic therapy, there was no statistically significant difference in ALC count post-RT (chemoRT: 0.33 ± 0.23 vs. RT: 0.48 ± 0.4, p = 0.2), but there was a lower ALC count pre-RT in the chemoRT group (0.5 ± 0.3 vs. 0.87 ± 0.52 for RT alone, p = 0.02). Post-RT ALC was not significantly associated with CR/PR vs. PD/SD, or with DSS, PFS, or OS. A greater drop in ALC Δ RT trended towards association with improved 90-day response (p = 0.066), without correlation with DSS, OS, or response at 30 days. Median dose per fraction was lower among patients that got pre-leukapheresis RT (2.25 vs. 2.5, p = 0.04), but total dose of bRT or number of fractions was not significantly different. Otherwise, the groups were similar in terms of stage, disease bulk, or comprehensive vs. focal bRT. The average decrease in ALC post-RT for patients who received bRT prior to apheresis was 0.215 K/µL, compared to 0.268 K/µL for patients who received bRT post-apheresis (p = 0.75). Treatment with pre-leukapheresis bRT or ALC Δ RT among these patients were not associated with worse DFS, PFS, or OS (p>0.15). CONCLUSION Post-bRT ALC and reduction in ALC during bRT is not associated with worse treatment response or survival outcomes after CAR-T cell treatment in aggressive B cell lymphoma. Pre-leukapheresis bRT did not appear to substantially impact ALC, and ALC Δ RT among these patients were not associated with worse outcomes.
Collapse
Affiliation(s)
- G S Manzar
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Y Wu
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S O Dudzinski
- Vanderbilt University School of Medicine, Nashville, TN
| | - M K Rooney
- Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - A Jallouk
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - A K Yoder
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - L F Nasr
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - J R Gunther
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - G Sallard
- Baylor College of Medicine, Houston, TX
| | - S Ahmed
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - L Fayad
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - R Nair
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - R Steiner
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - J Westin
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - L Nastoupil
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S S Neelapu
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - B Dabaja
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - C C Pinnix
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - P Strati
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - P Fang
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
4
|
Pinnix C, Dabaja B, Gunther J, Fang P, Wu S, Nastoupil L, Strati P, Nair R, Ahmed S, Steiner R, Westin J, Neelapu S, Rodriguez M, Lee H, Wang M, Fowler N, Flowers C, Feng L, Chi L, Esmaeli B. Response Adapted Ultra Low Dose Radiation Therapy for the Definitive Management of Orbital Indolent B-Cell Lymphoma. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.2322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
5
|
Wu S, Fang P, Huen A, Iyer S, Nair R, Steiner R, Castillo L, Duvic M, Ahmed S, Jain P, Fayad L, Strati P, Westin J, Neelapu S, Nastoupil L, Pinnix C, Dabaja B, Gunther J. Concurrent Radiation Therapy With the Antibody-Drug Conjugates Brentuximab Vedotin and Polatuzumab Vedotin. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
6
|
Steiner R, Banchs J, Koutroumpakis E, Becnel M, Gutierrez C, Strati P, Pinnix C, Feng L, Claussen C, Palaskas N, Karimzad K, Ahmed S, Neelapu S, Shpall E, Wang M, Vega F, Westin J, Nastoupil L, Deswal A. CARDIOVASCULAR EVENTS AMONG ADULT PATIENTS WITH AGGRESSIVE B‐CELL LYMPHOMA TREATED WITH STANDARD OF CARE AXICABTAGENE CILOLEUCEL AND TISAGENLECLEUCEL. Hematol Oncol 2021. [DOI: 10.1002/hon.177_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- R. Steiner
- MD Anderson Cancer Center Lymphoma & Myeloma Houston Texas USA
| | - J. Banchs
- MD Anderson Cancer Center Cardiology Houston USA
| | | | - M. Becnel
- MD Anderson Cancer Center Lymphoma & Myeloma Houston Texas USA
| | - C. Gutierrez
- MD Anderson Cancer Center Critical Care & Respiratory Care Houston Texas USA
| | - P. Strati
- MD Anderson Cancer Center Lymphoma & Myeloma Houston Texas USA
| | - C. Pinnix
- MD Anderson Cancer Center Radiation Oncology Houston Texas USA
| | - L. Feng
- MD Anderson Cancer Center Biostatistics Houston Texas USA
| | - C. Claussen
- MD Anderson Cancer Center Lymphoma & Myeloma Houston Texas USA
| | - N. Palaskas
- MD Anderson Cancer Center Cardiology Houston USA
| | - K. Karimzad
- MD Anderson Cancer Center Cardiology Houston USA
| | - S. Ahmed
- MD Anderson Cancer Center Lymphoma & Myeloma Houston Texas USA
| | - S. Neelapu
- MD Anderson Cancer Center Lymphoma & Myeloma Houston Texas USA
| | - E. Shpall
- MD Anderson Cancer Center Stem Cell Transplantation Houston Texas USA
| | - M. Wang
- MD Anderson Cancer Center Lymphoma & Myeloma Houston Texas USA
| | - F. Vega
- MD Anderson Cancer Center Hematopathology Houston Texas USA
| | - J. Westin
- MD Anderson Cancer Center Lymphoma & Myeloma Houston Texas USA
| | - L. Nastoupil
- MD Anderson Cancer Center Lymphoma & Myeloma Houston Texas USA
| | - A. Deswal
- MD Anderson Cancer Center Cardiology Houston USA
| |
Collapse
|
7
|
Liu Y, Augustyn A, Gunther J, Fang P, Nastoupil L, Ahmed S, Strati P, Nair R, Steiner R, Westin J, Rodriguez M, Neelapu S, Flowers C, Khoury J, Medeiros L, Dabaja B, Pinnix C. Radiation Therapy for Refractory High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.939] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
8
|
Fang P, Gunther J, Pinnix C, Dong W, Strati P, Nastoupil L, Fowler N, Steiner R, Nair R, Ahmed S, Westin J, Neelapu S, Ha C, Dabaja B. A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
9
|
Glober G, Gunther J, Milgrom S, Korivi B, Jensen C, Wagner-Bartak N, Lee H, Ahmed S, Nair R, Steiner R, Iyer S, Westin J, Fayad L, Rodriguez M, Neelapu S, Nastoupil L, Dabaja B, Pinnix C. Limited Utility of PET-CT and CT Imaging Beyond Treatment Completion in Limited Stage Hodgkin Lymphoma Patients. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
10
|
Jain P, Romaguera J, Nomie K, Zhang S, Wang L, Oriabure O, Wagner-Bartak N, Zhang L, Hagemeister F, Samaniego F, Westin J, Ju Lee H, Nastoupil L, Iyer S, Parmar S, Ok C, Kanagal-Shamanna R, Chen W, Thirumurthi S, Santos D, Badillo M, Fayad L, Neelapu S, Fowler N, Wang M. COMBINATION OF IBRUTINIB WITH RITUXIMAB (IR) IS HIGHLY EFFECTIVE IN PREVIOUSLY UNTREATED ELDERLY (>65 YEARS) PATIENTS (PTS) WITH MANTLE CELL LYMPHOMA (MCL) - PHASE II TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.11_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- P. Jain
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - J. Romaguera
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - K. Nomie
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - S. Zhang
- Genomic Medicine; UTMDACC; Houston United States
| | - L. Wang
- Genomic Medicine; UTMDACC; Houston United States
| | - O. Oriabure
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | | | - L. Zhang
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - F. Hagemeister
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - F. Samaniego
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - J. Westin
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - H. Ju Lee
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - L. Nastoupil
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - S. Iyer
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - S. Parmar
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - C. Ok
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | | | - W. Chen
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | | | - D. Santos
- Surgical Oncology; UTMDACC; Houston United States
| | - M. Badillo
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - L. Fayad
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - S. Neelapu
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - N. Fowler
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - M. Wang
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| |
Collapse
|
11
|
Strati P, Ahmed M, Fowler N, Hagemeister F, Fayad L, Rodriguez M, Samaniego F, Wang M, Westin J, Romaguera J, Noorani M, Phansalkar K, Cheah C, Feng L, Davis R, Nastoupil L, Neelapu S. PROGNOSTIC VALUE OF PRE-TREATMENT PET SCAN IN PATIENTS WITH FOLLICULAR LYMPHOMA RECEIVING FRONTLINE THERAPY. Hematol Oncol 2019. [DOI: 10.1002/hon.22_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- P. Strati
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - M. Ahmed
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - N. Fowler
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - F. Hagemeister
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - L. Fayad
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - M. Rodriguez
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - F. Samaniego
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - M. Wang
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - J.R. Westin
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - J. Romaguera
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - M. Noorani
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - K. Phansalkar
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - C. Cheah
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - L. Feng
- Biostatistics; MD Anderson Cancer Center; Houston United States
| | - R.E. Davis
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - L. Nastoupil
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - S.S. Neelapu
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| |
Collapse
|
12
|
Westin J, Nastoupil L, Hagemeister F, Fayad L, Young K, McDonnell T, Chuang H, Ahmed S, Nair R, Steiner R, Lee H, Rodriguez M, Parmar S, Green M, Neelapu S, Davis R. SMART START: RITUXIMAB, LENALIDOMIDE, AND IBRUTINIB ALONE PRIOR TO COMBINATION WITH CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.48_2629] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- J.R. Westin
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - L. Nastoupil
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - F. Hagemeister
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - L. Fayad
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - K. Young
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - T. McDonnell
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - H. Chuang
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - S. Ahmed
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - R. Nair
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - R. Steiner
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - H. Lee
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - M. Rodriguez
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - S. Parmar
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - M. Green
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - S. Neelapu
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - R. Davis
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| |
Collapse
|
13
|
Bachanova V, Westin J, Tam C, Borchmann P, Jaeger U, McGuirk J, Holte H, Waller E, Jaglowski S, Bishop M, Andreadis C, Foley S, Fleury I, Teshima T, Mielke S, Salles G, Ho P, Izutsu K, Maziarz R, Van Besien K, Kersten M, Wagner-Johnston N, Kato K, Corradini P, Han X, Agoulnik S, Chu J, Eldjerou L, Pacaud L, Schuster S. CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL-TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS. Hematol Oncol 2019. [DOI: 10.1002/hon.118_2630] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- V. Bachanova
- Division of Hematology; Oncology and Transplantation, University of Minnesota; Minneapolis United States
| | - J. Westin
- Department of Lymphoma & Meyloma; M.D. Anderson Cancer Center; Houston United States
| | - C. Tam
- Department of Haematology; Peter MacCallum Cancer Centre; Melbourne Australia
| | - P. Borchmann
- Department of Hematology/Oncology; University Hospital of Cologne; Cologne Germany
| | - U. Jaeger
- Department of Hematology/Hemostaseology; Medical University Vienna; Vienna Austria
| | - J. McGuirk
- Division of Hematologic Malignancies and Cellular Therapeutics; Kansas Hospital and Medical Center; Kansas City United States
| | - H. Holte
- Lymphoma Section; University of Oslo; Oslo Norway
| | - E. Waller
- Department of Stem Cell Transplantation and Immunology; Emory University School of Medicine; Atlanta United States
| | - S. Jaglowski
- Department of Internal Medicine; The Ohio State University; Columbus United States
| | - M. Bishop
- Section of Hematology/Oncology; University of Chicago; Chicago United States
| | - C. Andreadis
- Department of Hematology and Blood and Marrow Transplat; University of California San Francisco; San Francisco United States
| | - S.R. Foley
- Division of Clinical Pathology; McMaster University; Hamilton Canada
| | - I. Fleury
- Department of Hematology; Hôpital Maisonneuve-Rosemont; Montreal Canada
| | - T. Teshima
- Department of Hematology; Hokkaido University Hospital; Sapporo Japan
| | - S. Mielke
- Department of Internal Medicine; University Hospital Wuerzburg; Wuerzburg Germany
| | - G. Salles
- Hematology Department; Lyon-Sud Hospital Center; Pierre-Benite France
| | - P.J. Ho
- Department of Haematology; Royal Prince Alfred Hospital; Camperdown Australia
| | - K. Izutsu
- Department of Hematology; National Cancer Center Hospital; Tokyo Japan
| | - R. Maziarz
- Department of Hematology and Oncology; Oregon Health and Science University; Portland United States
| | - K. Van Besien
- Department of Medical Oncology; Weill Cornell Medicine; New York United States
| | - M.J. Kersten
- Department of Hematology; Academic Medical Center; Amsterdam Netherlands
| | - N. Wagner-Johnston
- Department of Oncology and Hematologic Malignancies; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center; Baltimore United States
| | - K. Kato
- Hematology; Oncology & Cardiovascular Medicine, Kyushu University; Fukuoka Prefecture Japan
| | - P. Corradini
- Department of Oncology and Hemato-oncology; University of Milan; Milan Italy
| | - X. Han
- Biomarkers and Diagnostics Biometrics; Novartis Pharmaceuticals Corporation; East Hanover United States
| | - S. Agoulnik
- Precision Medicine; Novartis Pharmaceuticals Corporation; Cambridge United States
| | - J. Chu
- Novartis Oncology; Novartis Pharmaceuticals Corporation; East Hanover United States
| | - L. Eldjerou
- Global Cell & Gene Medical Affairs; Novartis Pharmaceuticals Corporation; East Hanover United States
| | - L. Pacaud
- Novartis Oncology; Novartis Pharmaceuticals Corporation; East Hanover United States
| | - S. Schuster
- Division of Hematology Oncology; University of Pennsylvania; Philadelphia United States
| |
Collapse
|
14
|
Palomba M, Cartron G, Popplewell L, Ribrag V, Westin J, Chitra S, Huw L, Newberry K, Raval A, Xu J, Morschhauser F. SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB IN COMBINATION WITH TAZEMETOSTAT IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.203_2631] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- M.L. Palomba
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - G. Cartron
- Department of Clinical Hematology; CHU Montpellier; Montpellier France
| | - L. Popplewell
- Department of Hematology & Hematopoietic Cell Transplantation; City of Hope Comprehensive Cancer Center; Duarte CA United States
| | - V. Ribrag
- DITEP; Gustave Roussy Cancer Campus; Villejuif France
| | - J. Westin
- Department of Lymphoma/Myeloma; MD Anderson Cancer Center; Houston TX United States
| | - S. Chitra
- Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
| | - L. Huw
- Oncology Biomarker Development; Genentech, Inc.; South San Francisco CA United States
| | - K. Newberry
- Clinical Development; Epizyme; Cambridge MA United States
| | - A. Raval
- Oncology Biomarker Development; Genentech, Inc.; South San Francisco CA United States
| | - J. Xu
- Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
| | - F. Morschhauser
- Institute of Hematology - Transfusion; Centre Hospitalier Régional Universitaire de Lille; Lille France
| |
Collapse
|
15
|
Jaeger U, Tam C, Borchmann P, McGuirk J, Holte H, Waller E, Jaglowski S, Andreadis C, Foley S, Fleury I, Westin J, Teshima T, Mielke S, Salles G, Ho P, Izutsu K, Schuster S, Bachanova V, Maziarz R, Van Besien K, Kersten M, Wagner-Johnston N, Kato K, Corradini P, Tiwari R, Forcina A, Pacaud L, Bishop M. INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL IN THE JULIET TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.189_2631] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- U. Jaeger
- Hematology and Hemostaseology; and Comprehensive Cancer Center, Medical University of Vienna; Vienna Austria
| | - C. Tam
- Department of Hematology; Peter MacCallum Cancer Centre; Melbourne Australia
| | - P. Borchmann
- Department of Hematology/Oncology; University Hospital of Cologne; Cologne Germany
| | - J. McGuirk
- Division of Hematologic Malignancies and Cellular Therapeutics; Kansas Hospital and Medical Center; Kansas City United States
| | - H. Holte
- Lymphoma Section; University of Oslo, Oslo
| | - E. Waller
- Hematology and Medical Oncology; Medicine and Pathology, Emory University School of Medicine; Atlanta United States
| | - S. Jaglowski
- Department of Hematology; Ohio State University, Columbus
| | - C. Andreadis
- Department of Hematology and Blood and Marrow Transplant; University of California San Francisco; San Francisco United States
| | - S.R. Foley
- Division of Clinical Pathology; McMaster University; Hamilton Canada
| | - I. Fleury
- Department of Hematology; Hôpital Maisonneuve-Rosemont; Montreal Canada
| | - J. Westin
- Department of Lymphoma & Meyloma; MD Anderson Cancer Center; Houston United States
| | - T. Teshima
- Department of Hematology; Hokkaido University Hospital; Sapporo Japan
| | - S. Mielke
- Department of Internal Medicine; University Hospital Wuerzburg; Wuerzburg Germany
| | - G. Salles
- Department of Hematology/Oncology; Hospital Center Lyon-Sud; Pierre-Benite France
| | - P.J. Ho
- Department of Haematology; Royal Prince Alfred Hospital; Camperdown Australia
| | - K. Izutsu
- Department of Hematology; National Cancer Center Hospital; Tokyo Japan
| | - S. Schuster
- Division of Hematology Oncology; University of Pennsylvania; Philadelphia United States
| | - V. Bachanova
- Division of Hematology; Oncology and Transplantation, University of Minnesota; Minneapolis United States
| | - R. Maziarz
- Department of Hematology; Oregon Health and Science University; Portland United States
| | - K. Van Besien
- Department of Medical Oncology; Weill Cornell Medicine; New York United States
| | - M.J. Kersten
- Department of Hematology; Academic Medical Center; Amsterdam Netherlands
| | - N. Wagner-Johnston
- Department of Hematology/Oncology; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center; Baltimore United States
| | - K. Kato
- Department of Haematology; Kyushu University Hospital; Fukuoka Prefecture Japan
| | - P. Corradini
- Department of Oncology and Hemato-oncology; University of Milan; Milan Italy
| | - R. Tiwari
- Global Medical Affaris; Novartis Pharmaceuticals Corporation; Hyderabad India
| | - A. Forcina
- Novartis Oncology; Novartis Pharma AG; Basel Switzerland
| | - L. Pacaud
- Novartis Oncology; Novartis Pharmaceuticals Corporation; East Hanover United States
| | - M. Bishop
- Section of Hematology/Oncology; University of Chicago; Chicago United States
| |
Collapse
|
16
|
Strati P, Adkins S, Nastoupil L, Westin J, Hagemeister F, Fowler N, Lee H, Fayad L, Samaniego F, Ahmed S, Varma A, Arafat S, Johncy S, Kebriaei P, Mulanovich V, Ariza Heredia E, Neelapu S. CLINICAL IMPLICATIONS OF CYTOPENIAS BEYOND DAY 30 AFTER AXI-CEL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.120_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- P. Strati
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - S. Adkins
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - L. Nastoupil
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - J. Westin
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - F. Hagemeister
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - N. Fowler
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - H.J. Lee
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - L. Fayad
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - F. Samaniego
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - S. Ahmed
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - A. Varma
- Stem Cell Transplant; MD Anderson Cancer Center; Houston United States
| | - S. Arafat
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - S. Johncy
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| | - P. Kebriaei
- Stem Cell Transplant; MD Anderson Cancer Center; Houston United States
| | - V.E. Mulanovich
- Infectious Disease; MD Anderson Cancer Center; Houston United States
| | - E. Ariza Heredia
- Infectious Disease; MD Anderson Cancer Center; Houston United States
| | - S.S. Neelapu
- Lymphoma and Myeloma; MD Anderson Cancer Center; Houston United States
| |
Collapse
|
17
|
Westin J, Nastoupil L, Fayad L, Hagemeister F, Young K, McDonnell T, Neelapu S, Davis R, Green M, Ahmed S, Nair R, Steiner R, Lee H, Rodriguez M, Parmar S, Chuang H. VERY EARLY FDG PET/CT SCAN MAY PREDICT OUTCOMES IN RELAPSED OR REFRACTORY DLBCL PATIENTS TREATED WITH SALVAGE THERAPY. Hematol Oncol 2019. [DOI: 10.1002/hon.79_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- J.R. Westin
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - L. Nastoupil
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - L. Fayad
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - F. Hagemeister
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - K. Young
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - T. McDonnell
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - S. Neelapu
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - R.E. Davis
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - M. Green
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - S. Ahmed
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - R. Nair
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - R. Steiner
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - H. Lee
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - M. Rodriguez
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - S. Parmar
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| | - H. Chuang
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston United States
| |
Collapse
|
18
|
Wang M, Jain P, Zhang S, Nomie K, Wang L, Oriabure O, Nogueras Gonzales G, Zhang L, Wagner-Bartak N, Hagemeister F, Samaniego F, Westin J, Lee H, Nastoupil L, Ok C, Kanagal-Shamanna R, Chen W, Thirumurthi S, Santos D, Badillo M, Fayad L, Neelapu S, Fowler N, Romaguera J. IBRUTINIB WITH RITUXIMAB (IR) AND SHORT COURSE R-HYPERCVAD/MTX IS VERY EFFICACIOUS IN PREVIOUSLY UNTREATED YOUNG PTS WITH MANTLE CELL LYMPHOMA (MCL). Hematol Oncol 2019. [DOI: 10.1002/hon.12_2629] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- M. Wang
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - P. Jain
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - S. Zhang
- Genomic Medicine; University of Texas MD Anderson Cancer Center; Houston United States
| | - K. Nomie
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - L. Wang
- Genomic Medicine; University of Texas MD Anderson Cancer Center; Houston United States
| | - O. Oriabure
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - G. Nogueras Gonzales
- Biostatistics; University of Texas MD Anderson Cancer Center; Houston United States
| | - L. Zhang
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - N. Wagner-Bartak
- Nuclear Medicine; University of Texas MD Anderson Cancer Center; Houston United States
| | - F. Hagemeister
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - F. Samaniego
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - J. Westin
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - H.J. Lee
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - L. Nastoupil
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - C. Ok
- Hemato-pahtology; University of Texas MD Anderson Cancer Center; Houston United States
| | - R. Kanagal-Shamanna
- Hemato-pahtology; University of Texas MD Anderson Cancer Center; Houston United States
| | - W. Chen
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - S. Thirumurthi
- Gastroenterology; University of Texas MD Anderson Cancer Center; Houston United States
| | - D. Santos
- Surgical Oncology; University of Texas MD Anderson Cancer Center; Houston United States
| | - M. Badillo
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - L. Fayad
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - S. Neelapu
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - N. Fowler
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - J. Romaguera
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| |
Collapse
|
19
|
Younes A, Batlevi C, Cohen J, Kelly K, Landsburg D, Patel K, Phillips T, Smith S, Westin J, Ma A, Grayson D, Barta S. DOSE FINDING STUDY TO ASSESS SAFETY, PK AND EFFICACY OF FIMEPINOSTAT (CUDC-907) WITH VENETOCLAX OR RITUXIMAB PLUS BENDAMUSTINE IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.9_2632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Younes
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - C.L. Batlevi
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - J.B. Cohen
- Hematology & Medical Oncology; Emory University Winship Cancer Institute; Atlanta United States
| | - K. Kelly
- Department of Medicine; University of Southern California, Norris Cancer Center Hospital; Los Angeles United States
| | - D.J. Landsburg
- Department of Medicine; University of Pennsylvania, Perelman Center; Philadelphia United States
| | - K. Patel
- Oncology; Swedish Cancer Institute; Seattle United States
| | - T. Phillips
- Rogel Cancer Center; University of Michigan; Ann Arbor United States
| | - S. Smith
- Hematology/Oncology; University of Chicago; Chicago United States
| | - J. Westin
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston United States
| | - A.W. Ma
- Research & Development; Curis, Inc.; Lexington United States
| | - D. Grayson
- Research & Development; Curis, Inc.; Lexington United States
| | - S. Barta
- Department of Medicine; University of Pennsylvania, Perelman Center; Philadelphia United States
| |
Collapse
|
20
|
Jain P, Kanagal-Shamanna R, Zhang S, Ok C, Nogueras Gonzalez G, Gonzalez-Pagan O, Ghorab A, Boddu P, Chen W, Lee HJ, Nomie K, Fayad L, Westin J, Nastoupil L, Patel K, Ahmed S, Iyer S, Parmar S, Champlin R, Neelapu S, Medeiros J, Romaguera J, Fowler N, Wang L, Wang M. COMPREHENSIVE ANALYSIS OF PROGNOSTIC FACTORS, OUTCOMES AND MUTATION PROFILE IN PATIENTS WITH AGGRESSIVE HISTOLOGY (BLASTOID/PLEOMORPHIC) OR TRANSFORMED MANTLE CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.49_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- P. Jain
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | | | - S. Zhang
- Genomic Medicine; UTMDACC; Houston United States
| | - C. Ok
- Hematopathology; UTMDACC; Houston United States
| | | | | | - A. Ghorab
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - P. Boddu
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - W. Chen
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - H. Ju Lee
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - K. Nomie
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - L. Fayad
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - J. Westin
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - L. Nastoupil
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - K. Patel
- Hematopathology; UTMDACC; Houston United States
| | - S. Ahmed
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - S.P. Iyer
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - S. Parmar
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - R. Champlin
- Stem Cell Transplantation; UTMDACC; Houston United States
| | - S. Neelapu
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | | | - J. Romaguera
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - N. Fowler
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - L. Wang
- Genomic Medicine; UTMDACC; Houston United States
| | - M.L. Wang
- Lymphoma and Myeloma; UT MD Anderson Cancer Center; Houston United States
| |
Collapse
|
21
|
Pinnix C, Gunther J, Milgrom S, Cruz Chamorro R, Medeiros L, Khoury J, Amini B, Fanale M, Neelapu S, Lee H, Westin J, Fowler N, Nastoupil L, Dabaja B. Excellent Outcomes after Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.06.234] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
22
|
Christopherson K, Gunther J, Milgrom S, Wong P, Ning M, Nastoupil L, Neelapu S, Fowler N, Fanale M, Westin J, Oki Y, Khoury J, Dabaja B, Pinnix C. Primary Gastric Diffuse Large B-Cell Lymphoma Treated with Abbreviated Chemoimmunotherapy and Contemporary Radiation Therapy has Excellent Outcomes with Minimal Toxicity. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
23
|
Sansone M, Wiman Å, Karlberg ML, Brytting M, Bohlin L, Andersson LM, Westin J, Nordén R. Molecular characterization of a nosocomial outbreak of influenza B virus in an acute care hospital setting. J Hosp Infect 2018; 101:30-37. [PMID: 29909095 PMCID: PMC7114871 DOI: 10.1016/j.jhin.2018.06.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2018] [Accepted: 06/04/2018] [Indexed: 01/21/2023]
Abstract
Aim To describe a hospital outbreak of influenza B virus (InfB) infection during season 2015/2016 by combining clinical and epidemiological data with molecular methods. Methods Twenty patients diagnosed with InfB from a hospital outbreak over a four-week-period were included. Nasopharyngeal samples (NPS) positive for InfB by multiplex real-time polymerase chain reaction were sent for lineage typing and whole genome sequencing (WGS). Medical records were reviewed retrospectively for data regarding patient characteristics, localization, exposure and outcome, and assembled into a timeline. In order to find possible connections to the hospital outbreak, all patients with a positive NPS for influenza from the region over an extended time period were also reviewed. Findings All 20 cases of InfB were of subtype B/Yamagata, and 17 of 20 patients could be linked to each other by either shared room or shared ward. WGS was successful or partially successful for 15 of the 17 viral isolates, and corroborated the epidemiological link supporting a close relationship. In the main affected ward, 19 of 75 inpatients were infected with InfB during the outbreak period, resulting in an attack rate of 25%. One probable case of influenza-related death was identified. Conclusion InfB may spread within an acute care hospital, and advanced molecular methods may facilitate assessment of the source and extent of the outbreak. A multi-faceted approach, including rapid diagnosis, early recognition of outbreak situations, simple rules for patient management and the use of regular infection control measures, may prevent nosocomial transmission of influenza virus.
Collapse
Affiliation(s)
- M Sansone
- Institute of Biomedicine, Department of Infectious Diseases, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
| | - Å Wiman
- Public Health Agency of Sweden, Solna, Sweden
| | | | - M Brytting
- Public Health Agency of Sweden, Solna, Sweden
| | - L Bohlin
- Department of Internal Medicine, Kungalv Hospital, Kungalv, Sweden
| | - L-M Andersson
- Institute of Biomedicine, Department of Infectious Diseases, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - J Westin
- Institute of Biomedicine, Department of Infectious Diseases, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - R Nordén
- Institute of Biomedicine, Department of Infectious Diseases, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| |
Collapse
|
24
|
Ludmir E, Milgrom S, Westin J, Oki Y, Fayad L, Pinnix C, Dabaja B, Nastoupil L. Primary Breast Diffuse Large B-Cell Lymphoma: Treatment Strategies and Patterns of Failure. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
25
|
Milgrom S, Pinnix C, Sheu T, Qiao W, Fowler N, Westin J, Nastoupil L, Hagemeister F, Oki Y, Fanale M, Fayad L, Lee H, Hosing C, Nieto Y, Shpall E, Dabaja B. Radiation As an Effective Salvage Therapy for Secondary CNS Lymphoma. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
26
|
Sheu T, Milgrom S, Dabaja B, Andraos T, Chi L, Nastoupil L, Fowler N, Westin J, Neelapu S, Lee H, Hagemeister F, Oki Y, Fanale M, Fayad L, Turturro F, Samaniego F, Pinnix C. Consolidative Radiation Dose De-escalation in Primary CNS Lymphoma for Patients with an Incomplete Response to Methotrexate Based Chemotherapy. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
27
|
Schuster S, Bishop M, Tam C, Waller E, Borchmann P, Mcguirk J, Jäger U, Jaglowski S, Andreadis C, Westin J, Fleury I, Bachanova V, Foley S, Ho P, Mielke S, Holte H, Anak O, Pacaud L, Awasthi R, Tai F, Salles G, Maziarz R. GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)-AN INTERIM ANALYSIS. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_6] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- S.J. Schuster
- Lymphoma Program, Abramson Cancer Center; University of Pennsylvania; Philadelphia USA
| | - M.R. Bishop
- Hematopoietic Cellular Therapy Program; The University of Chicago Medicine; Chicago USA
| | - C. Tam
- Division of Hematology and Oncology; Peter MacCallum Cancer Centre; Melbourne Australia
| | - E.K. Waller
- Department of Hematology and Medical Oncology; Emory University School of Medicine; Atlanta USA
| | - P. Borchmann
- Department of Internal Medicine; University Hospital of Cologne; Cologne Germany
| | - J. Mcguirk
- Department of Blood and Bone Marrow Transplant; The University of Kansas Cancer Center; Kansas City USA
| | - U. Jäger
- Department of Medicine I, Division of Hematology and Hemostaseology; Medical University of Vienna; Vienna Austria
| | - S. Jaglowski
- Department of Internal Medicine; The Ohio State University Wexner Medical Center; Columbus USA
| | - C. Andreadis
- Helen Diller Family Comprehensive Cancer Center; University of California San Francisco Medical Center; San Francisco USA
| | - J. Westin
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston USA
| | - I. Fleury
- Department of Medicine, University of Montreal; Maisonneuve-Rosemont Hospital CIUSSS East; Montreal Canada
| | - V. Bachanova
- Department of Medicine; University of Minnesota; Minneapolis USA
| | - S.R. Foley
- Department of Medicine; McMaster University; Hamilton Canada
| | - P.J. Ho
- Institute of Haematology; Royal Prince Alfred Hospital & Sydney University; Sydney Australia
| | - S. Mielke
- Medizinische Klinik und Poliklinik II; Universitatsklinikum Würzburg; Würzburg Germany
| | - H. Holte
- Department of Oncology; Oslo University Hospital; Oslo Norway
| | - O. Anak
- Global Drug Development; Novartis Pharma AG; Basel Switzerland
| | - L. Pacaud
- Global Drug Development; Novartis Pharma AG; Basel Switzerland
| | - R. Awasthi
- PK Sciences; Novartis Pharmaceuticals Corporation; East Hanover USA
| | - F. Tai
- Biostatistics; Novartis Pharmaceuticals Corporation; East Hanover USA
| | - G. Salles
- Hospices Civils de Lyon; Université de Lyon; Lyon France
| | - R. Maziarz
- Center for Hematologic Malignancies, Knight Cancer Institute; Oregon Health & Science University; Portland USA
| |
Collapse
|
28
|
Wang M, Lee H, Thirumurthi S, Chuang H, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Chen W, Oriabure O, Feng L, Zhou S, Huang S, Li S, Zhang L, Badillo M, Wu L, Ahmed M, Yan F, Nomie K, Lam L, Addison A, Romaguera J. IBRUTINIB-RITUXIMAB FOLLOWED BY REDUCED CHEMO-IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_132] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- M.L. Wang
- Department of Lymphoma/Myeloma, Department of Stem Cell Transplantation and Cellular Therapy; University of Texas MD Anderson; Houston USA
| | - H. Lee
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - S. Thirumurthi
- Department of Gastroenterology; University of Texas MD Anderson; Houston USA
| | - H. Chuang
- Department of Nuclear Medicine; University of Texas MD Anderson; Houston USA
| | - F. Hagemeister
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - J. Westin
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - L. Fayad
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - F. Samaniego
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - F. Turturro
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - W. Chen
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - O. Oriabure
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - L. Feng
- Department of Biostatistics; University of Texas MD Anderson; Houston USA
| | - S. Zhou
- Department of Biostatistics; University of Texas MD Anderson; Houston USA
| | - S. Huang
- Department of Interventional Radiology; University of Texas MD Anderson; Houston USA
| | - S. Li
- Department of Hematopathology; University of Texas MD Anderson; Houston USA
| | - L. Zhang
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - M. Badillo
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - L. Wu
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - M. Ahmed
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - F. Yan
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - K. Nomie
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - L. Lam
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - A. Addison
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| | - J. Romaguera
- Department of Lymphoma/Myeloma; University of Texas MD Anderson; Houston USA
| |
Collapse
|
29
|
Westin J, Fayad L, Oki Y, Nastoupil L, Hagemeister F, Turturro F, Lee H, Rodriguez A, Young K, McDonnell T, Ford R, Neelapu S, Davis R. RITUXIMAB, LENALIDOMIDE, AND IBRUTINIB ALONE AND COMBINED WITH CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_51] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- J.R. Westin
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - L. Fayad
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - Y. Oki
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - L. Nastoupil
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - F. Hagemeister
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - F. Turturro
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - H.J. Lee
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - A. Rodriguez
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - K.H. Young
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - T. McDonnell
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - R. Ford
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - S. Neelapu
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - R.E. Davis
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| |
Collapse
|
30
|
Nastoupil L, Westin J, Fowler N, Fanale M, Samaniego F, Oki Y, Obi C, Cao J, Cheng X, Ma M, Wang Z, Chu F, Feng L, Zhou S, Davis R, Neelapu S. HIGH RESPONSE RATES WITH PEMBROLIZUMAB IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: INTERIM RESULTS OF AN ON OPEN-LABEL, PHASE II STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_108] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- L.J. Nastoupil
- Lymphoma/Myeloma, UT MD Anderson Cancer Center; Houston USA
| | - J. Westin
- Lymphoma/Myeloma, UT MD Anderson Cancer Center; Houston USA
| | - N. Fowler
- Lymphoma/Myeloma, UT MD Anderson Cancer Center; Houston USA
| | - M. Fanale
- Lymphoma/Myeloma, UT MD Anderson Cancer Center; Houston USA
| | - F. Samaniego
- Lymphoma/Myeloma, UT MD Anderson Cancer Center; Houston USA
| | - Y. Oki
- Lymphoma/Myeloma, UT MD Anderson Cancer Center; Houston USA
| | - C. Obi
- Lymphoma/Myeloma, UT MD Anderson Cancer Center; Houston USA
| | - J. Cao
- Lymphoma/Myeloma, UT MD Anderson Cancer Center; Houston USA
| | - X. Cheng
- Lymphoma/Myeloma, UT MD Anderson Cancer Center; Houston USA
| | - M. Ma
- Lymphoma/Myeloma, UT MD Anderson Cancer Center; Houston USA
| | - Z. Wang
- Lymphoma/Myeloma, UT MD Anderson Cancer Center; Houston USA
| | - F. Chu
- Lymphoma/Myeloma, UT MD Anderson Cancer Center; Houston USA
| | - L. Feng
- Biostatistics; UT MD Anderson Cancer Center; Houston USA
| | - S. Zhou
- Biostatistics; UT MD Anderson Cancer Center; Houston USA
| | - R.E. Davis
- Lymphoma/Myeloma, UT MD Anderson Cancer Center; Houston USA
| | - S.S. Neelapu
- Lymphoma/Myeloma, UT MD Anderson Cancer Center; Houston USA
| |
Collapse
|
31
|
Chaudhry M, Nastoupil L, Samaniego F, Neelapu S, Hagemeister F, Fanale M, Fayad L, Westin J, Oki Y, Feng L, Fowler N. TREATMENT WITH COMBINATION OF LENALIDOMIDE AND RITUXIMAB ACHIEVES DURABLE RESPONSES IN A LONG TERM FOLLOW UP OF PATIENTS WITH INDOLENT NON-HODGKIN'S LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_79] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M. Chaudhry
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston USA
| | - L. Nastoupil
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston USA
| | - F. Samaniego
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston USA
| | - S.S. Neelapu
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston USA
| | - F.B. Hagemeister
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston USA
| | - M.A. Fanale
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston USA
| | - L. Fayad
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston USA
| | - J.R. Westin
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston USA
| | - Y. Oki
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston USA
| | - L. Feng
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston USA
| | - N. Fowler
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston USA
| |
Collapse
|
32
|
Casasnovas R, Westin J, Thieblemont C, Zijlstra J, Hill B, De La Cruz Vicente F, Choquet S, Caimi P, Kaplan J, Canales M, Kuruvilla J, Follows G, van den Neste E, Meade J, Wrigley B, Devlin M, Saint-Martin J, Nippgen C, Gardner H, Shacham S, Kauffman M, Maerevoet M. A PHASE 2B RANDOMIZED STUDY OF SINGLE AGENT SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). Hematol Oncol 2017. [DOI: 10.1002/hon.2438_53] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | - J. Westin
- Lymphoma & Myeloma, MD Anderson Cancer Center; Houston USA
| | - C. Thieblemont
- APHP, Hemato-Oncology; Hopital Saint-Louis; Paris France
| | - J. Zijlstra
- Lunenburg Lymphoma Phase-I Consortium; VU University Medical Center; Amsterdam The Netherlands
| | - B. Hill
- Taussig Cancer Institute; Cleveland Clinic; Cleveland USA
| | | | - S. Choquet
- Hematology; Hospital Pitie Salpetriere; Paris France
| | - P. Caimi
- Seidman Cancer Center; University Hospital; Cleveland USA
| | - J. Kaplan
- Feinberg School of Medicine; Northwestern University; Chicago USA
| | - M. Canales
- Hematology; Hospital Universitario La Paz; Madrid Spain
| | - J. Kuruvilla
- Hematology; Princess Margaret Hospital; Toronto Canada
| | - G. Follows
- NHS Foundation Trust; Cambridge University Teaching Hospitals; Cambridge UK
| | - E. van den Neste
- Hematology; Cliniques Universitaires UCL Saint-Luc; Brussels Belgium
| | - J. Meade
- Clinical, Karyopharm Therapeutics; Newton USA
| | - B. Wrigley
- Clinical, Karyopharm Therapeutics; Newton USA
| | - M. Devlin
- Clinical, Karyopharm Therapeutics; Newton USA
| | | | - C. Nippgen
- Clinical, Karyopharm Therapeutics; Newton USA
| | - H. Gardner
- Clinical, Karyopharm Therapeutics; Newton USA
| | - S. Shacham
- Clinical, Karyopharm Therapeutics; Newton USA
| | - M. Kauffman
- Clinical, Karyopharm Therapeutics; Newton USA
| | - M. Maerevoet
- Hematology; Institute Jules Bordet; Brussels Belgium
| |
Collapse
|
33
|
Fowler N, Samaniego F, Turturro F, Neelapu S, Forbes S, Westin J, Fayad L, Fanale M, Feng L, Arafat J, Neal E, Hagemeister F, Nastoupil L. THE IMMUNOLOGIC DOUBLET OF LENALIDOMIDE PLUS OBINUTUZUMAB IS HIGHLY ACTIVE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA, RESULTS OF A PHASE I/II STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_140] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- N.H. Fowler
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - F. Samaniego
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - F. Turturro
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - S. Neelapu
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - S. Forbes
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - J. Westin
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - L. Fayad
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - M. Fanale
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - L. Feng
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - J. Arafat
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - E. Neal
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - F. Hagemeister
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - L. Nastoupil
- Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| |
Collapse
|
34
|
Westin J, Oki Y, Nastoupil L, Fayad L, Neelapu S, Turturro F, Hagemeister F, Rodriguez A, Lee H, Young K, McDonnell T, Ford R, Davis R. LENALIDOMIDE AND OBINUTUZUMAB WITH CHOP FOR NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA: PHASE I/II RESULTS. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_138] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- J.R. Westin
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston USA
| | - Y. Oki
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston USA
| | - L. Nastoupil
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston USA
| | - L. Fayad
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston USA
| | - S. Neelapu
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston USA
| | - F. Turturro
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston USA
| | | | - A. Rodriguez
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston USA
| | - H.J. Lee
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston USA
| | - K.H. Young
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston USA
| | - T. McDonnell
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston USA
| | - R. Ford
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston USA
| | - R.E. Davis
- Lymphoma & Myeloma; MD Anderson Cancer Center; Houston USA
| |
Collapse
|
35
|
Bjarnason A, Lindh M, Westin J, Andersson LM, Baldursson O, Kristinsson KG, Gottfredsson M. Utility of oropharyngeal real-time PCR for S. pneumoniae and H. influenzae for diagnosis of pneumonia in adults. Eur J Clin Microbiol Infect Dis 2017; 36:529-536. [PMID: 27822652 PMCID: PMC5309271 DOI: 10.1007/s10096-016-2829-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2016] [Accepted: 10/20/2016] [Indexed: 12/11/2022]
Abstract
A lack of sensitive tests and difficulties obtaining representative samples contribute to the challenge in identifying etiology in pneumonia. Upper respiratory tract swabs can be easily collected and analyzed with real-time PCR (rtPCR). Common pathogens such as S. pneumoniae and H. influenzae can both colonize and infect the respiratory tract, complicating the interpretation of positive results. Oropharyngeal swabs were collected (n = 239) prospectively from adults admitted to hospital with pneumonia. Analysis with rtPCR targeting S. pneumoniae and H. influenzae was performed and results compared with sputum cultures, blood cultures, and urine antigen testing for S. pneumoniae. Different Ct cutoff values were applied to positive tests to discern colonization from infection. Comparing rtPCR with conventional testing for S. pneumoniae in patients with all tests available (n = 57) resulted in: sensitivity 87 %, specificity 79 %, PPV 59 % and NPV 94 %, and for H. influenzae (n = 67): sensitivity 75 %, specificity 80 %, PPV 45 % and NPV 94 %. When patients with prior antimicrobial exposure were excluded sensitivity improved: 92 % for S. pneumoniae and 80 % for H. influenzae. Receiver operating characteristic curve analysis demonstrated for S. pneumoniae: AUC = 0.65 (95 % CI 0.51-0.80) and for H. influenzae: AUC = 0.86 (95 % CI 0.72-1.00). Analysis of oropharyngeal swabs using rtPCR proved both reasonably sensitive and specific for diagnosing pneumonia caused by S. pneumoniae and H. influenzae. This method may be a useful diagnostic adjunct to other methods and of special value in patients unable to provide representative lower airway samples.
Collapse
Affiliation(s)
- A Bjarnason
- Faculty of Medicine, University of Iceland, Reykjavik, Vatnsmyrarvegi 16, 101, Reykjavik, Iceland
- Departments of Medicine, Microbiology and Virology, Landspitali University Hospital, 101, Reykjavik, Iceland
| | - M Lindh
- Department of Infectious Diseases/Clinical Virology, University of Gothenburg, Medicinaregatan 3a-5b, 40530, Gothenburg, Sweden
| | - J Westin
- Department of Infectious Diseases/Clinical Virology, University of Gothenburg, Medicinaregatan 3a-5b, 40530, Gothenburg, Sweden
| | - L-M Andersson
- Department of Infectious Diseases/Clinical Virology, University of Gothenburg, Medicinaregatan 3a-5b, 40530, Gothenburg, Sweden
| | - O Baldursson
- Departments of Medicine, Microbiology and Virology, Landspitali University Hospital, 101, Reykjavik, Iceland
| | - K G Kristinsson
- Faculty of Medicine, University of Iceland, Reykjavik, Vatnsmyrarvegi 16, 101, Reykjavik, Iceland
- Departments of Medicine, Microbiology and Virology, Landspitali University Hospital, 101, Reykjavik, Iceland
| | - M Gottfredsson
- Faculty of Medicine, University of Iceland, Reykjavik, Vatnsmyrarvegi 16, 101, Reykjavik, Iceland.
- Departments of Medicine, Microbiology and Virology, Landspitali University Hospital, 101, Reykjavik, Iceland.
- Division of Infectious Diseases, Landspitali University Hospital, Fossvogur, 108, Reykjavik, Iceland.
| |
Collapse
|
36
|
Janku F, Vergilio J, Salhia B, Fanale M, Oki Y, Huang H, Westin J, He J, Nahas M, Mughal T, Miller V, Stephens P, Raina A, Garrido-Laguna I, Meric-Bernstam F, Ross J, Liang W. Comprehensive genomic profiling reveals recurrent XPO1 mutations and other alterations in archival samples of patients with Hodgkin lymphoma. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32705-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
37
|
Gustavsson L, Nordén R, Letelier Molnegren V, Lindh M, Westin J, Andersson LM. Longer duration of viral shedding following infection with a novel norovirus GII.4 strain. J Clin Virol 2016. [DOI: 10.1016/j.jcv.2016.08.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
38
|
Braide I, Westin J, Hasselbalch H, Hippe E, Lisse I, Röckert L, Swolin B, Zador G. Demonstrated Benefit of Continuous Interferon-Alpha-2b Therapy in Hairy Cell Leukemia. A Two-Year Follow-Up. Leuk Lymphoma 2016; 5:23-31. [PMID: 27463206 DOI: 10.3109/10428199109068101] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Interferon-alpha-2b (IFN) was given to a series of 50 patients with hairy cell leukemia (HCL). The IFN dose for both induction and maintenance was 2.0 × 10(6) IU/m(2) s.c. three times weekly. At 24 months 38 patients remained in the study. The proportion of complete responders (CR) increased during the follow-up, and had at 24 months reached 58%, while 28% at the same time had a partial (PR) and 14% a minor response (MR). During the two years of continuous IFN treatment none of the 38 patients showed any signs of relapse. The response rate was similar between splenectomized (n = 15) and non-splenectomized (n = 23) patients, but the rise in platelets was much steeper and reached a significantly higher plateau in patients, who previously had undergone splenectomy. The IFN therapy was generally well tolerated, but when evaluated at 24 months at least some (mostly mild) toxicity was noted in 76% of the patients. None of the patients developed neutralizing antibodies to IFN.
Collapse
Affiliation(s)
- I Braide
- a Departments of Medicine II (Section of Hematology), Clinical Chemistry, and Pathology, Sahlgrenska Hospital, Gothenburg University, Gothenburg, Sweden; Department of Medicine and Hematology, Gentofte Hospital, Hellerup, Denmark; Department of Pathology, Hvidovre Hospital, Denmark; and Schering-Plough AB, Stockholm, Sweden
| | - J Westin
- a Departments of Medicine II (Section of Hematology), Clinical Chemistry, and Pathology, Sahlgrenska Hospital, Gothenburg University, Gothenburg, Sweden; Department of Medicine and Hematology, Gentofte Hospital, Hellerup, Denmark; Department of Pathology, Hvidovre Hospital, Denmark; and Schering-Plough AB, Stockholm, Sweden
| | - H Hasselbalch
- a Departments of Medicine II (Section of Hematology), Clinical Chemistry, and Pathology, Sahlgrenska Hospital, Gothenburg University, Gothenburg, Sweden; Department of Medicine and Hematology, Gentofte Hospital, Hellerup, Denmark; Department of Pathology, Hvidovre Hospital, Denmark; and Schering-Plough AB, Stockholm, Sweden
| | - E Hippe
- a Departments of Medicine II (Section of Hematology), Clinical Chemistry, and Pathology, Sahlgrenska Hospital, Gothenburg University, Gothenburg, Sweden; Department of Medicine and Hematology, Gentofte Hospital, Hellerup, Denmark; Department of Pathology, Hvidovre Hospital, Denmark; and Schering-Plough AB, Stockholm, Sweden
| | - I Lisse
- a Departments of Medicine II (Section of Hematology), Clinical Chemistry, and Pathology, Sahlgrenska Hospital, Gothenburg University, Gothenburg, Sweden; Department of Medicine and Hematology, Gentofte Hospital, Hellerup, Denmark; Department of Pathology, Hvidovre Hospital, Denmark; and Schering-Plough AB, Stockholm, Sweden
| | - L Röckert
- a Departments of Medicine II (Section of Hematology), Clinical Chemistry, and Pathology, Sahlgrenska Hospital, Gothenburg University, Gothenburg, Sweden; Department of Medicine and Hematology, Gentofte Hospital, Hellerup, Denmark; Department of Pathology, Hvidovre Hospital, Denmark; and Schering-Plough AB, Stockholm, Sweden
| | - B Swolin
- a Departments of Medicine II (Section of Hematology), Clinical Chemistry, and Pathology, Sahlgrenska Hospital, Gothenburg University, Gothenburg, Sweden; Department of Medicine and Hematology, Gentofte Hospital, Hellerup, Denmark; Department of Pathology, Hvidovre Hospital, Denmark; and Schering-Plough AB, Stockholm, Sweden
| | - G Zador
- a Departments of Medicine II (Section of Hematology), Clinical Chemistry, and Pathology, Sahlgrenska Hospital, Gothenburg University, Gothenburg, Sweden; Department of Medicine and Hematology, Gentofte Hospital, Hellerup, Denmark; Department of Pathology, Hvidovre Hospital, Denmark; and Schering-Plough AB, Stockholm, Sweden
| |
Collapse
|
39
|
Magnusson J, Norder H, Riise GC, Andersson LM, Brittain-Long R, Westin J. Incidence of Hepatitis E Antibodies in Swedish Lung Transplant Recipients. Transplant Proc 2016; 47:1972-6. [PMID: 26293083 DOI: 10.1016/j.transproceed.2015.04.092] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2015] [Accepted: 04/07/2015] [Indexed: 12/22/2022]
Abstract
BACKGROUND Hepatitis E virus (HEV) is an important cause of acute and chronic hepatitis in solid organ transplant recipients, especially liver transplant recipients. However, less is known of the incidence and prevalence of HEV in lung transplant recipients. METHODS In a prospective study, 62 patients were observed during the first year after lung transplantation. Sera were analyzed for anti-HEV immunoglobulin G (IgG) and IgM at 12 months after transplantation. Samples positive for anti-HEV were also analyzed for HEV RNA by polymerase chain reaction. Pretransplantation samples were analyzed for patients with detectable anti-HEV 1 year after transplantation. RESULTS Eight patients (13%) had anti-HEV IgG at the 12-month follow-up sample. HEV RNA could not be detected in any of these samples. One of these patients seroconverted during the follow-up without developing acute or chronic hepatitis. CONCLUSIONS Our results show that the prevalence of HEV antibodies among Swedish lung transplant recipients is similar when compared to the general population. It also suggests that the risk for HEV antibody seroconversion during first year is limited.
Collapse
Affiliation(s)
- J Magnusson
- Department of Internal Medicine/Respiratory Medicine and Allergology, Institute of Medicine, University of Gothenburg, Sweden.
| | - H Norder
- Department of Infectious Diseases/Clinical Virology, Institute of Biomedicine, University of Gothenburg, Sweden
| | - G C Riise
- Department of Internal Medicine/Respiratory Medicine and Allergology, Institute of Medicine, University of Gothenburg, Sweden
| | - L-M Andersson
- Department of Infectious Diseases/Clinical Virology, Institute of Biomedicine, University of Gothenburg, Sweden
| | - R Brittain-Long
- Department of Infectious Diseases, Aberdeen Royal Infirmary, Aberdeen, Scotland
| | - J Westin
- Department of Infectious Diseases/Clinical Virology, Institute of Biomedicine, University of Gothenburg, Sweden
| |
Collapse
|
40
|
Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Jurczyszyn A, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim CS, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O'Gorman P, Terpos E, McCarthy P, Dimopoulos M, Moreau P, Orlowski RZ, Miguel JS, Anderson KC, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson PG. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia 2015; 30:1005-17. [DOI: 10.1038/leu.2015.356] [Citation(s) in RCA: 175] [Impact Index Per Article: 19.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2015] [Revised: 09/11/2015] [Accepted: 09/24/2015] [Indexed: 11/09/2022]
|
41
|
Pinnix C, Dabaja B, Milgrom S, Smith G, Reed V, Arzu I, Westin J, Rondon G, Hosing C, Nieto Y, Ahmed S. Salvage Radiation Therapy Prior to Stem Cell Transplantation for Chemorefractory B-Cell Lymphoma. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
42
|
|
43
|
Tao R, Shihadeh F, Pinnix C, Arzu I, Reed V, Oki Y, Westin J, Fayad L, Medeiros L, Rodriguez A, Dabaja B. Does Skeletal Presentation Make a Difference in Outcomes of Diffuse Large B-cell Lymphoma? A Review of the 25-Year Experience With Treating Primary Bone Lymphoma. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
44
|
Pinnix C, Westin J, Ahmed M, Reed V, Romaguerra J, Oki Y, Rodriguez M, Fayad L, Hagemeister F, Kwak L, Medeiros L, Francesco T, Davis R, Chuang H, Davis R, Dabaja B. The Role of Radiation Therapy in the Treatment of Primary Mediastinal B Cell Lymphoma Treated with Rituximab containing Regimens. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.2673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
45
|
Janku F, Garrido-Laguna I, Velez-Bravo V, Falchook G, Subbiah V, Hong D, Oki Y, Westin J, Nunez C, Fayad L, Kwak L, Neelapu S, Shpall E, Wheler J, Lang W, Salhia B, Meric-Bernstam F, Kurzrock R, Fanale M. Significant Activity of the mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat in Heavily Pretreated Refractory Hodgkin Lymphoma Patients. Klin Padiatr 2014. [DOI: 10.1055/s-0034-1371153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
46
|
Lindh M, Arnholm B, Björkman P, Hellstrand K, Lagging M, Nilsson S, Wahlberg T, Wallmark E, Weiland O, Wejstål R, Westin J, Widell A, Norkrans G. Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin. J Viral Hepat 2013; 20:e82-9. [PMID: 23490394 DOI: 10.1111/jvh.12014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/01/2012] [Accepted: 08/01/2012] [Indexed: 12/09/2022]
Abstract
The treatment durations for hepatitis C are guided by the analysis of hepatitis C virus (HCV) RNA in blood at certain time points. This multicentre, randomized open label trial evaluated the utility and performance of individualized treatment durations guided by viral decline rates in 103 patients with HCV genotype 1 infection. Pegylated interferon 2a and ribavirin were given as standard of care (SOC) for 24, 48 or 72 weeks or as dynamic treatment (DT) for 24-72 weeks. The DT duration was based on the time point when log HCV RNA would reach 0 log copies/mL, as estimated by the second-phase decline. The rate of sustained virologic response was 63% for SOC and 54% for DT, but this difference was not significant in multiple regression analysis taking predictive factors such as interleukin-28B genotypes, age and baseline viremia into account (P = 0.45). The mean required treatment time per cured patient was 51 weeks for DT as compared with 58 weeks for SOC (P = 0.22) when given per protocol (n = 95) and was significantly shorter (42 vs 51 weeks) among patients who achieved undetectable HCV RNA (P = 0.01). We conclude that DT was feasible and increased efficiency. The estimated time point for 0 log viral copies/mL is a new and quantitative response variable, which may be used as a complement to the qualitative variable rapid virologic response. The outcome parameter treatment weeks per cured patient could become a useful tool for comparing treatment efficiency also in the era of directly acting antivirals.
Collapse
Affiliation(s)
- M Lindh
- Department of Infectious Diseases, University of Gothenburg, Gothenburg, Sweden.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Sansone M, Andersson M, Brittain-Long R, Andersson LM, Olofsson S, Westin J, Lindh M. Rhinovirus infections in western Sweden: a four-year molecular epidemiology study comparing local and globally appearing types. Eur J Clin Microbiol Infect Dis 2013; 32:947-54. [PMID: 23435753 PMCID: PMC7087832 DOI: 10.1007/s10096-013-1832-x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2012] [Accepted: 01/24/2013] [Indexed: 11/07/2022]
Abstract
Human rhinovirus (HRV) is a highly prevalent pathogen and a major cause of acute respiratory tract infection (ARTI). HRV express less seasonality than other viral ARTIs, which typically appear as seasonal epidemics lasting for 1–2 months. The aim of this study was to investigate the seasonal patterns of HRV types over four consecutive years in one geographic region. HRV identified in respiratory samples from 114 patients over a four-year period were analysed by VP4/VP2 sequencing. HRV-A was found in 64, HRV-B in 11 and HRV-C in 37 cases. Overall, 33 different HRV-A types, nine B types and 21 C types were found. As many as 21 of the HRV types appeared during several seasons, with a maximum time-span of four years. Some types appeared during successive seasons and, in some cases, phylogenetic analysis indicated extended periods of circulation locally. Most of the strains were closely related to HRV identified in other parts of the world during the same time period. HRV strains that circulate locally represent many types and seem to reflect that HRV infections are highly globalised. The existence of simultaneous or successive epidemics with different HRV types in combination with the ability of each type to remain in the local population over extended periods of time may contribute to explaining the high rate of HRV infections.
Collapse
Affiliation(s)
- M Sansone
- Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Guldhedsgatan 10B, 413 36 Gothenburg, Sweden
| | | | | | | | | | | | | |
Collapse
|
48
|
Guedj H, Guedj J, Negro F, Lagging M, Westin J, Bochud PY, Bibert S, Neumann AU. The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin. J Viral Hepat 2012. [PMID: 22676361 DOI: 10.1111/j.1365-2893.2011.01569] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Hepatitis C viral (HCV) kinetics after initiation of interferon-based therapy provide valuable insights for understanding virus pathogenesis, evaluating treatment antiviral effectiveness and predicting treatment outcome. Adverse effects of liver fibrosis and steatosis on sustained virological response have been frequently reported, yet their impacts on the early viral kinetics remain unclear. In this study, associations between histology status and early viral kinetics were assessed in 149 HCV genotype 1-infected patients treated with pegylated interferon alfa-2a and ribavirin (DITTO trial). In multivariate analyses adjusted for critical factors such as IL28B genotype and baseline viral load, presence of significant fibrosis (Ishak stage > 2) was found to independently reduce the odds of achieving an initial reduction (calculated from day 0 to day 4) in HCV RNA of ≥2 logIU/mL (adjusted OR 0.03, P = 0.004) but was not associated with the second-phase slope of viral decline (calculated from day 8 to day 29). On the contrary, presence of liver steatosis was an independent risk factor for not having a rapid second-phase slope, that is, ≥0.3 logIU/mL/week (adjusted OR 0.22, P = 0.012) but was not associated with the first-phase decline. Viral kinetic modelling theory suggests that significant fibrosis primarily impairs the treatment antiviral effectiveness in blocking viral production by infected cells, whereas the presence of steatosis is associated with a lower net loss of infected cells. Further studies will be necessary to identify the biological mechanisms underlain by these findings.
Collapse
Affiliation(s)
- H Guedj
- Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
| | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Guedj H, Guedj J, Negro F, Lagging M, Westin J, Bochud PY, Bibert S, Neumann AU. The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin. J Viral Hepat 2012; 19:488-96. [PMID: 22676361 DOI: 10.1111/j.1365-2893.2011.01569.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Hepatitis C viral (HCV) kinetics after initiation of interferon-based therapy provide valuable insights for understanding virus pathogenesis, evaluating treatment antiviral effectiveness and predicting treatment outcome. Adverse effects of liver fibrosis and steatosis on sustained virological response have been frequently reported, yet their impacts on the early viral kinetics remain unclear. In this study, associations between histology status and early viral kinetics were assessed in 149 HCV genotype 1-infected patients treated with pegylated interferon alfa-2a and ribavirin (DITTO trial). In multivariate analyses adjusted for critical factors such as IL28B genotype and baseline viral load, presence of significant fibrosis (Ishak stage > 2) was found to independently reduce the odds of achieving an initial reduction (calculated from day 0 to day 4) in HCV RNA of ≥2 logIU/mL (adjusted OR 0.03, P = 0.004) but was not associated with the second-phase slope of viral decline (calculated from day 8 to day 29). On the contrary, presence of liver steatosis was an independent risk factor for not having a rapid second-phase slope, that is, ≥0.3 logIU/mL/week (adjusted OR 0.22, P = 0.012) but was not associated with the first-phase decline. Viral kinetic modelling theory suggests that significant fibrosis primarily impairs the treatment antiviral effectiveness in blocking viral production by infected cells, whereas the presence of steatosis is associated with a lower net loss of infected cells. Further studies will be necessary to identify the biological mechanisms underlain by these findings.
Collapse
Affiliation(s)
- H Guedj
- Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Alsiö Å, Jannesson A, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K, Westin J, Hellstrand K, Norkrans G, Lagging M. Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection. Eur J Clin Microbiol Infect Dis 2011; 31:1631-5. [DOI: 10.1007/s10096-011-1486-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2011] [Accepted: 11/03/2011] [Indexed: 10/15/2022]
|